Why Increasing CJC or Tesamorelin Dose Won't Raise GH More

In this video, we delve into the common misconception that increasing the doses of CJC or Tesamorelin will lead to higher growth hormone (GH) levels. The speaker explains that while both CJC and Tesamorelin are effective peptides for stimulating GH release, simply increasing their dosage does not correlate with a proportional increase in GH levels. This is primarily due to the body's regulatory mechanisms which ensure that hormone levels remain stable and within a certain range.

​

The video further discusses how the body's feedback systems work to regulate hormone secretion. It emphasizes that there are optimal dosing strategies for CJC and Tesamorelin that maximize their effectiveness without the need for excessive doses. This understanding can help users achieve better results in their growth hormone therapy while minimizing unnecessary risks associated with higher dosages. Overall, the video provides valuable insights into the science of peptide therapy and the importance of adhering to recommended dosing guidelines.1. Increasing doses of CJC or Tesamorelin doesn't raise GH levels proportionally.

1. The body's regulatory mechanisms maintain stable hormone levels.
2. Optimal dosing strategies exist for effective GH stimulation.
3. Higher doses can lead to risks without additional benefits.
4. Understanding peptide therapy is crucial for effective treatment.